New drug psoriasis does well in trials
A new drug targeting a different part of the immune system shows promise in treating psoriasis.
Unlike other drugs on the market, this treatment, termed IMO-8400, zeroes in on toll-like receptors (TLRs), which are proteins that play a key role in activating immune response. Results from a recent clinical trial of IMO-8400 indicate that the medication, a subcutaneous injection, can safely and effectively improve the symptoms of plaque psoriasis.
The 12-week, placebo-controlled trial involved 32 patients with psoriasis. IMO-8400 reduced the severity of psoriatic lesions by 50 percent in nine patients, and as much as 75 percent in four patients, according to Idera Pharmaceuticals, the drug's manufacturer. None of the patients enrolled in the study reported any adverse side effects.